263
Participants
Start Date
August 21, 2023
Primary Completion Date
March 31, 2027
Study Completion Date
March 31, 2027
BGB-A3055
Administered intravenously
Tislelizumab
Administered intravenously
Chemotherapy
Administered in accordance with relevant local guidelines and/or prescribing information.
Chris Obrien Lifehouse, Camperdown
Icon Cancer Centre South Brisbane, South Brisbane
Linear Clinical Research, Nedlands
Seoul National University Bundang Hospital, BundangGu SeongnamSi
Centre de Lutte Contre Le Cancer Institut Bergonie, Bordeaux
Ico Site Rene Gauducheau, SaintHerblain
Institut Curie, Paris
Liaoning Cancer Hospital and Institute, Shenyang
Rui Jin Hospital Shanghai Jiao Tong University School of Medicinejiading Branch, Shanghai
Jiangsu Province Hospital, Nanjing
Tianjin Medical University Cancer Institute and Hospital, Tianjin
The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou
Fujian Cancer Hospital, Fuzhou
Chongqing University Cancer Hospital, Chongqing
Henan Cancer Hospital, Zhengzhou
Advent Health Cancer Institute, Orlando
University of Iowa Hospitals and Clinics, Iowa City
John Theurer Cancer Center Hackensack University Medical Center, Hackensack
The University of Texas Md Anderson Cancer Center, Houston
Next Dallas, Irving
Fred Hutchinson Cancer Research Center, Seattle
Changzhi Peoples Hospital, Changzhi
Samsung Medical Center, GangnamGu
Severance Hospital Yonsei University Health System, SeodaemunGu
Seoul National University Hospital, Seoul
Asan Medical Center, SongpaGu
Lead Sponsor
BeiGene
INDUSTRY